Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2010

View Archived Issues

QTc interval is prolonged in myotonic dystrophy type 1 / News in Context

Phase II data show efficacy of Gilead Sciences' Quad anti-HIV regimen through 48 weeks

TransVax reduces cytomegalovirus viremia in phase II trial

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Chitosan-GP is efficacious in ongoing trial in patients with articular cartilage lesions

Acucela and Otsuka Pharma to codevelop and -promote OPA-6566 for glaucoma

Cylene begins phase I trial of CX-4945 in multiple myeloma

FDA grants orphan drug status for iCo-009 in visceral leishmaniasis

Phase III trial of Budesonide MMX in ulcerative colitis meets primary endpoint

Prefilled syringes of Relistor approved in U.S., E.U. and Canada

Medivation and Astellas begin phase III MDV-3100 trial in advanced prostate cancer

Astellas files for Japanese approval of darexaban for VTE prevention

Enrollment complete in phase IIa trial of XOMA-052 in type 2 diabetes

Zeria submits acotiamide for approval in Japan to treat functional dyspepsia

Unibioscreen claims novel cardiotonic steroid derivatives

Baxter obtains approval in Austria for Preflucel influenza vaccine

New voltage-gated potassium K(V)7.2/3 channel modulators described

Cleveland BioLabs reports on second safety study of CBLB-502

AstraZeneca begins enrollment in phase III OSKIRA program for fostamatinib in RA

Novel benzoxazinone derivatives claimed by NeuroSearch

Conbriza is approved in Spain for postmenopausal osteoporosis

Astellas and UMN Pharma enter definitive agreement for flu vaccines

Pieris, sanofi-aventis and Sanofi Pasteur to develop anticalin therapeutics

Astellas Pharma patents new 17-beta-HSD 5 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...